Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Intensity Therapeutics Inc. (NASDAQ:INTS – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.00.

A number of brokerages have recently issued reports on INTS. Weiss Ratings reiterated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. Citigroup reiterated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Finally, HC Wainwright boosted their price target on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th.

Get Intensity Therapeutics alerts:

View Our Latest Report on INTS

Intensity Therapeutics Stock Down 6.3%

Shares of INTS opened at $3.42 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 5.00. The stock has a market capitalization of $11.15 million, a price-to-earnings ratio of -0.96 and a beta of 2.76. Intensity Therapeutics has a 1 year low of $3.27 and a 1 year high of $43.50. The business’s 50 day simple moving average is $4.17 and its 200-day simple moving average is $4.66.

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.24). As a group, equities analysts expect that Intensity Therapeutics will post -2.64 earnings per share for the current fiscal year.

About Intensity Therapeutics

(Get Free Report)

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors.

Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors.

Further Reading

• Five stocks we like better than Intensity Therapeutics
• Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
• The Bull Case for Amprius Technologies Just Got Stronger
• CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
• CoreWeave Comes With Risks: Analysts Split on What Matters Most

Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.